Patent ID: 9376492
Filing Date: 2016-06-28
CPC Classification: A61K,A61P,C07K,G01N

Claim Text:
1. A method of treating cancer comprising administering to a subject having cancer a therapeutically effective quantity of an antagonist of desmoglein 2 (Dsg2), wherein said antagonist is an antibody or antibody fragment that specifically binds to the amino acid sequence: TQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYR (SEQ ID NO: 1), or a biologically active fragment thereof, of the non-cell adhesion recognition (non-CAR) sequence of the EC2 domain of Dsg2, and wherein said antagonist reduces the epithelial-mesenchymal transition (EMT) promoting function of Dsg2.